Home > Neurology > EAN 2020 > Epilepsy > Sustained seizure reductions with cannabidiol for Lennox-Gastaut syndrome

Sustained seizure reductions with cannabidiol for Lennox-Gastaut syndrome

Add-on cannabidiol (CBD) in patients with Lennox-Gastaut syndrome (LGS) produced sustained seizure reductions, with no new safety concerns [1]. This was concluded from 3-year results of an open-label extension of 2 randomised controlled trials.

LGS is a rare and severe form of epileptic encephalopathy characterised by multiple seizure types, characteristic EEG findings with bursts of slow spike-wave complexes or generalised paroxysmal fast activity, and intellectual impairment. Seizures are often drug-resistant. Efficacy and safety of CBD as an add-on anticonvulsant therapy in LGS were demonstrated in two 14-week phase 3 randomised controlled trials: GWPCARE3 and GWPCARE4 [2,3]. Patients who completed either of these trials could enter the open-label extension trial GWPCARE...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on